Made with FlowPaper - Flipbook Maker
Trinity College Friday 27th September 2024 OXFORD VACCINE GROUP1 Contents Foreword 3 Session One Encapsulated bacteria: Hib, meningococcus 7 Session Two Pneumococcus and Respiratory Viruses 15 Session Three Typhoid and Paratyphoid 24 Session Four Endemics and Pandemics 32 Session Five Vaccines at Scale 4123 This document summarises the content and presentations given at the OVG 30 symposium on 26 September 2024. The event was held in celebration of 30 years of scientific research and development, and it delivered an outstanding showcase of our achievements, by the people who contributed to its success. Since its inception in 1994, OVG has grown into a vibrant community of around 200 staff and students, dedicated to advancing vaccine science, education, and public engagement. The OVG mission, crafted through collaborative efforts, has guided the group in its pursuit of excellence in vaccine research and development. OVG has focused not only on the scientific aspects but also on the educational and service components that are integral to its work. Today, we are fortunate to have 15 outstanding Principal Investigators leading various programs within OVG. Their leadership, combined with the efforts of our dedicated staff from diverse research and support areas, enables us to deliver impactful results. Our comprehensive approach, often referred to as the “full stack,” allows us to navigate all phases of vaccine development, from discovery to policy and public engagement. Our achievements are a testament to the collaborative spirit within OVG and our partnerships with institutions worldwide. Despite the challenges, including the financial demands of sustaining a large team, we have thrived thanks to the high-quality research grants secured by our talented team members. As we reflect on our contributions, such as the significant reduction in under-five mortality rates, we recognise the ongoing challenges and the need for continued efforts. The recent pandemic has underscored the importance of our work and the necessity of being prepared for future public health threats. The symposium provided a comprehensive insight into the remarkable journey of the Oxford Vaccine Group. Thank you for your support and for joining us to celebrate 30 years of ground-breaking achievements. Professor Sir Andrew Pollard Director of the Oxford Vaccine Group Foreword Andrew Pollard with Richard MoxonThe OVG mission is to improve health through immunisation, using our expertise in scientific discovery, and the development, clinical testing and laboratory evaluation of vaccines; and to share our knowledge. The Oxford Vaccine Group Mission67 Encapsulated bacteria: Hib, meningococcus Session Chair: Professor Richard Moxon Session OneNext >